Northrup et al. evaluated ghrelin and anamorelin on tumour growth in mouse models of lung cancer, and found that neither compound could effect tumour growth until the end of the intervention despite the significantly increased GH and IGF-1 levels [57]. The gene discussed is IGF1; the disease is lung carcinoma.